Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

BACKGROUND: Nintedanib is a potent, oral angiokinase inhibitor that targets VEGF, PDGF and FGF signalling, as well as RET and Flt3. The maximum tolerated dose of nintedanib was evaluated in a phase I study of treatment-refractory patients with advanced solid tumours. In this preplanned subanalysis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mross, Klaus, Büchert, Martin, Frost, Annette, Medinger, Michael, Stopfer, Peter, Studeny, Matus, Kaiser, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105047/
https://www.ncbi.nlm.nih.gov/pubmed/25012508
http://dx.doi.org/10.1186/1471-2407-14-510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105047/
https://www.ncbi.nlm.nih.gov/pubmed/25012508
http://dx.doi.org/10.1186/1471-2407-14-510

Ejemplares similares